Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms

Area of Science:

• Child Psychiatry
• Developmental Neuroscience
• Pharmacology

Background:

• Autism Spectrum Disorder (ASD) presents significant behavioral challenges.
• Effective pharmacological interventions for core ASD symptoms remain a critical research area.
• Understanding the impact of psychotropic medications on learning in young children with ASD is essential.

Purpose of the Study:

• To evaluate the efficacy and safety of haloperidol in treating behavioral symptoms of autism in young children.
• To assess the effects of haloperidol on cognitive functions, specifically discrimination learning, in this population.
• To determine the optimal therapeutic dosage range and identify any potential adverse effects.

Main Methods:

• A double-blind, placebo-controlled study design was employed.
• Forty children diagnosed with autism, aged 2.33 to 6.92 years, participated.
• Haloperidol administration involved doses ranging from 0.5 to 3.0 mg/day (0.019 to 0.217 mg/kg/day).

Main Results:

• Haloperidol treatment led to significant reductions in behavioral symptoms associated with autism.
• A notable general clinical improvement was observed in children receiving haloperidol.
• The study demonstrated enhanced facilitation and retention of discrimination learning in the laboratory setting with haloperidol.
• No adverse effects were reported at the therapeutic doses administered.

Conclusions:

• Haloperidol is an effective treatment for reducing behavioral symptoms in young autistic children.
• The medication shows promise in improving overall clinical status and cognitive functions, including learning, in this population.
• Therapeutic doses of haloperidol appear safe for use in young children with autism, with no observed adverse effects.